The goal of this clinical trial is to learn if Infliximab Biosimilar Remsima works to treat moderate to severe plaque Psoriasis in adults. It will also learn about the safety of the drug. The main questions it aims to answer are: Does Infliximab-dyyb Biosimilar (Remsima) works to treat moderate to severe plaque Psoriasis in adults in reducing disease severity and relapses? What medical problems do participants have when taking Remsima? Participants will: be injected Infliximab Biosimilar Remsima weekly for 4 weeks and then fortnightly till 24 weeks They will be followed for efficacy and safety and lab tests at week 4, 14, 24 and 52.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
104
Subcutaneous injections of Infliximab-dyyb Biosimilar (Remsima) were injected weekly for 4 weeks and then fortnightly for 24 weeks
Department of Dermatology, Services Institute of Medical Sciences/ Services Hospital
Lahore, Punjab Province, Pakistan
At least 50% reduction in PASI
PASI should reduce to at least 50% of baseline (pre-treatment)
Time frame: 14 weeks
At least 50% reduction in DLQI
DLQI (Dermatology Life Quality Index) should reduce to at least 50% of baseline (pre-treatment)
Time frame: 14 weeks
Maintenance of At least 50% reduction in PASI and DLQI
Maintenance of At least 50% reduction in PASI and DLQI from baseline (pre-treatment)
Time frame: 24 weeks
Maintenance of At least 50% reduction in PASI and DLQI
Maintenance of At least 50% reduction in PASI and DLQI from baseline (pre-treatment)
Time frame: 52 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.